<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><object-id pub-id-type="doi">10.7554/eLife.42542.002</object-id><label>Table 1.</label><caption><title>Characteristics of study participants, by HCV genotype group.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>HCV genotype</th><th>All</th><th>1a</th><th>1b</th><th>2a</th><th>2b</th><th>3a</th><th>4a</th><th>Others</th></tr></thead><tbody><tr><td valign="top">&#8195;<italic>N</italic></td><td valign="top"><italic>8729</italic></td><td valign="top"><italic>3548 (41)</italic></td><td valign="top"><italic>1924 (22)</italic></td><td valign="top"><italic>304 (3)</italic></td><td valign="top"><italic>472 (5)</italic></td><td valign="top"><italic>1839 (21)</italic></td><td valign="top"><italic>193 (2)</italic></td><td valign="top"><italic>449 (5)</italic></td></tr><tr><td valign="top">Europeans <break/>Asians <break/>Africans <break/>Others</td><td valign="top">6704 (77) <break/>1103 (13) <break/>723 (8) <break/>199 (2)</td><td valign="top">2987 (84) <break/>59 (2) <break/>421 (12) <break/>81 (2)</td><td valign="top">1133 (59) <break/>577 (30) <break/>192 (10) <break/>22 (1)</td><td valign="top">100 (33) <break/>197 (65) <break/>7 (2) <break/>0 (0)</td><td valign="top">421 (89) <break/>15 (3) <break/>25 (5) <break/>11 (2)</td><td valign="top">1635 (89) <break/>111 (6) <break/>19 (1) <break/>74 (4)</td><td valign="top">178 (92) <break/>2 (1) <break/>8 (4) <break/>5 (3)</td><td valign="top">250 (56) <break/>142 (32) <break/>51 (11) <break/>6 (1)</td></tr><tr><td valign="top">Cirrhosis</td><td valign="top">2410 (28)</td><td valign="top">978 (28)</td><td valign="top">536 (28)</td><td valign="top">35 (12)</td><td valign="top">77 (16)</td><td valign="top">629 (34)</td><td valign="top">60 (31)</td><td valign="top">95 (21)</td></tr><tr><td valign="top">Male sex</td><td valign="top">5605 (64)</td><td valign="top">2434 (69)</td><td valign="top">1096 (57)</td><td valign="top">141 (46)</td><td valign="top">301 (64)</td><td valign="top">1230 (67)</td><td valign="top">143 (74)</td><td valign="top">260 (58)</td></tr><tr><td valign="top">SVR</td><td valign="top">7702 (88)</td><td valign="top">3240 (91)</td><td valign="top">1773 (92)</td><td valign="top">273 (90)</td><td valign="top">426 (90)</td><td valign="top">1452 (79)</td><td valign="top">153 (79)</td><td valign="top">385 (86)</td></tr></tbody></table><table-wrap-foot><fn><p>Data are indicated as number (percent); SVR: sustained virological response after treatment.</p></fn></table-wrap-foot></table-wrap>